• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks Hitting New 52-Week Lows Today

    1/3/22 1:35:03 PM ET
    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Professional Services
    Consumer Discretionary
    EDP Services
    Technology
    Get the next $AGIL alert in real time by email

     

     

    On Monday morning, 60 companies achieved new lows for the year.

    Points of Interest From Today's 52-Week Lows And Highs:

    • Ginkgo Bioworks Holdings (NYSE:DNA) was the largest firm on a market cap basis to set a new 52-week low.
    • Palisade Bio (NASDAQ:PALI) is the smallest company on a market cap basis to set a new 52-week low.
    • Applied Therapeutics (NASDAQ:APLT)'s stock moved significantly downwards, trading down 29.61% to reach a new 52-week low.
    • Nerdy (NYSE:NRDY) shares actually gained 0.0%, rebounding after it reached its 52-week low.

    These stocks set new 52-week lows during the first half-hour of trading on Monday:

    • Ginkgo Bioworks Holdings (NYSE:DNA) stock hit a new 52-week low of $7.95. The stock was up 2.65% on the session.
    • NovoCure (NASDAQ:NVCR) shares were up 6.53% for the day, having made a 52-week low of $74.67.
    • Natura &Co Holding (NYSE:NTCO) shares hit a yearly low of $8.71. The stock was down 2.1% on the session.
    • Olo (NYSE:OLO) shares set a new 52-week low of $20.09. The stock traded up 0.65%.
    • Sana Biotechnology (NASDAQ:SANA) stock achieved a new 52-week low on Monday morning, hitting $14.83 and moving up 0.12%.
    • Vertex (NASDAQ:VERX) shares reached a new 52-week low of $15.60 on Monday morning, moving up 4.3%.
    • Editas Medicine (NASDAQ:EDIT) shares were up 3.73% for the day, having made a 52-week low of $25.91.
    • Sorrento Therapeutics (NASDAQ:SRNE) stock set a new 52-week low of $4.57 on Monday, moving up 4.19%.
    • Inovio Pharmaceuticals (NASDAQ:INO) shares were up 2.91% for the day, having made a 52-week low of $4.92.
    • Burning Rock Biotech (NASDAQ:BNR) stock achieved a new 52-week low on Monday morning, hitting $9.16 and moving up 3.54%.
    • Companhia Brasileira (NYSE:CBD) shares reached a new 52-week low of $3.70 on Monday morning, moving down 6.77%.
    • AlloVir (NASDAQ:ALVR) shares set a new yearly low of $12.57 this morning. The stock was up 2.7% on the session.
    • Humacyte (NASDAQ:HUMA) shares moved up 1.24% on Monday to hit a new 52-week low of $7.02, drifting up 1.24%.
    • Dyne Therapeutics (NASDAQ:DYN) shares moved up 1.56% on Monday to hit a new 52-week low of $11.51, drifting up 1.56%.
    • BlackSky Technology (NYSE:BKSY) stock hit $4.34 on Monday morning, setting a new 52-week low for a change of up 2.0%.
    • Annexon (NASDAQ:ANNX) shares set a new yearly low of $11.05 this morning. The stock was up 1.48% on the session.
    • Taysha Gene Therapies (NASDAQ:TSHA) shares hit a yearly low of $11.09. The stock was down 0.86% on the session.
    • Cleanspark (NASDAQ:CLSK) shares reached a new 52-week low of $9.43 on Monday morning, moving up 3.15%.
    • AppHarvest (NASDAQ:APPH) shares moved up 1.67% on Monday to hit a new 52-week low of $3.75, drifting up 1.67%.
    • Nerdy (NYSE:NRDY) stock dropped to a yearly low on Monday of $4.33. Shares traded 0.0% (flat).
    • Blackrock Income Trust (NYSE:BKT) shares set a new 52-week low of $5.61. The stock traded down 0.55%.
    • Passage Bio (NASDAQ:PASG) shares were up 1.1% for the day, having made a 52-week low of $6.12.
    • Newcourt Acquisition (NASDAQ:NCAC) shares were down 0.2% for the day, having made a 52-week low of $9.87.
    • Momentus (NASDAQ:MNTS) shares set a new yearly low of $4.06 this morning. The stock was up 2.39% on the session.
    • VPC Impact Acquisition (NYSE:VPCC) shares moved down 5.76% on Monday to hit a new 52-week low of $9.50, drifting down 5.76%.
    • P3 Health Partners (NASDAQ:PIII) shares made a new 52-week low of $6.52 on Monday. The stock was down 4.26% for the day.
    • Zenvia (NASDAQ:ZENV) shares reached a new 52-week low of $6.51 on Monday morning, moving up 2.65%.
    • Humanigen (NASDAQ:HGEN) stock drifted up 0.13% on Monday morning to hit a new 52-week low of $3.56.
    • AgileThought (NASDAQ:AGIL) shares set a new yearly low of $4.61 this morning. The stock was up 2.29% on the session.
    • WAVE Life Sciences (NASDAQ:WVE) shares set a new 52-week low of $3.02. The stock traded up 0.96%.
    • VirnetX Holding (NYSE:VHC) shares reached a new 52-week low of $2.53 on Monday morning, moving down 0.38%.
    • Applied Therapeutics (NASDAQ:APLT) shares set a new 52-week low of $6.00. The stock traded down 29.61%.
    • Platinum Group Metals (AMEX:PLG) shares hit a yearly low of $1.55. The stock was up 5.38% on the session.
    • Tyme Technologies (NASDAQ:TYME) stock dropped to a yearly low on Monday of $0.60. Shares traded up 4.13%.
    • Waitr Hldgs (NASDAQ:WTRH) stock hit $0.73 on Monday morning, setting a new 52-week low for a change of up 1.23%.
    • GT Biopharma (NASDAQ:GTBP) stock achieved a new 52-week low on Monday morning, hitting $2.89 and moving up 1.31%.
    • Ocean Power Technologies (AMEX:OPTT) shares hit a yearly low of $1.47. The stock was up 6.08% on the session.
    • HCW Biologics (NASDAQ:HCWB) shares reached a new 52-week low of $2.30 on Monday morning, moving up 0.72%.
    • IN8bio (NASDAQ:INAB) shares set a new yearly low of $4.19 this morning. The stock was down 4.43% on the session.
    • Nova Vision Acquisition (NASDAQ:NOVV) stock hit a new 52-week low of $9.86. The stock was up 0.2% on the session.
    • HOOKIPA Pharma (NASDAQ:HOOK) stock hit a yearly low of $2.28. The stock was 0.0% (flat) for the day.
    • Clarus Therapeutics Hldgs (NASDAQ:CRXT) stock hit a yearly low of $2.32. The stock was down 3.29% for the day.
    • AGM Gr Hldgs (NASDAQ:AGMH) shares set a new 52-week low of $2.30. The stock traded up 3.33%.
    • Xtant Medical Holdings (AMEX:XTNT) shares moved up 1.09% on Monday to hit a new 52-week low of $0.55, drifting up 1.09%.
    • Regulus Therapeutics (NASDAQ:RGLS) shares hit a yearly low of $0.31. The stock was up 0.67% on the session.
    • Fangdd Network Group (NASDAQ:DUO) stock hit a new 52-week low of $0.40. The stock was down 1.1% on the session.
    • Bright Minds Biosciences (NASDAQ:DRUG) shares set a new yearly low of $3.07 this morning. The stock was down 2.84% on the session.
    • Vaccinex (NASDAQ:VCNX) shares hit a yearly low of $1.02. The stock was up 8.65% on the session.
    • Soligenix (NASDAQ:SNGX) shares were up 4.5% for the day, having made a 52-week low of $0.66.
    • IDW Media Holdings (AMEX:IDW) shares reached a new 52-week low of $1.86 on Monday morning, moving down 7.0%.
    • Palisade Bio (NASDAQ:PALI) stock hit $1.26 on Monday morning, setting a new 52-week low for a change of up 6.15%.
    •  

    Be sure to monitor Benzinga for the news traders need! And for even more up-to-date info on 52-week lows and highs, check out Benzinga Pro. This cutting-edge market research platform alerts traders of which stocks are trading near their 52-week highs and lows each morning - and delivers lots of other actionable data. Learn more here.

    Get the next $AGIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGIL
    $AGMH
    $ALVR
    $ANNX

    CompanyDatePrice TargetRatingAnalyst
    Passage Bio Inc.
    $PASG
    4/21/2026Buy → Hold
    TD Cowen
    Passage Bio Inc.
    $PASG
    4/21/2026$7.00Buy → Neutral
    Chardan Capital Markets
    Passage Bio Inc.
    $PASG
    4/21/2026$8.00Outperform → Neutral
    Wedbush
    Bright Minds Biosciences Inc.
    $DRUG
    4/13/2026$145.00Buy
    Jefferies
    Palisade Bio Inc.
    $PALI
    4/9/2026$7.00Outperform
    Wolfe Research
    Passage Bio Inc.
    $PASG
    3/31/2026$30.00Outperform
    Oppenheimer
    Palisade Bio Inc.
    $PALI
    3/26/2026$7.00Buy
    H.C. Wainwright
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    More analyst ratings

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

    - Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care -  - Positions Humacyte to advance discussions with corporate partners regarding international and indication-specific rights to Symvess – - Existing terms related to U.S. distribution of Symvess remain unchanged DURHAM, N.C., April 24, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has realigned the ex-U.S. rights to Symvess (acellular tissue engineered vessel) through an amendment to its distribution agreement with Fresenius

    4/24/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 18 new employees. The awards were made as an inducement material to the new employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 320,900 shares of Dyne's common stock at a per share exercise price equal to the closing price of Dyne's common stock on The Nasdaq

    4/23/26 4:05:00 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senmiao Technology Appoints David Nichols as Strategic Advisor to Advance AI Data Center, Digital Infrastructure, and New Energy Strategy

    Veteran Infrastructure Finance and Carbon Markets Executive Brings Public Company Leadership, Hyperscale Data Center Development, and Capital Markets Structuring Expertise to AIHS Growth Platform Chengdu, China, April 23, 2026 (GLOBE NEWSWIRE) -- Senmiao Technology Limited ("Senmiao" or the "Company") (NASDAQ:AIHS) today announced the appointment of David Nichols as Strategic Advisor, effective immediately. In this role, Mr. Nichols will drive the Company's business development and strategic execution across its AI data center solutions, digital infrastructure, and new energy initiatives, with a particular focus on power infrastructure origination, capital formation, and institutional pa

    4/23/26 8:00:00 AM ET
    $AIHS
    $APPH
    Finance: Consumer Services
    Finance
    Farming/Seeds/Milling
    Consumer Staples

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kersten Dirk sold $219,170 worth of shares (10,952 units at $20.01) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    4/23/26 4:15:03 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Rhodes Jason P

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    4/22/26 6:27:22 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kersten Dirk

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    4/21/26 4:15:06 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Passage BIO downgraded by TD Cowen

    TD Cowen downgraded Passage BIO from Buy to Hold

    4/21/26 9:31:55 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Passage BIO downgraded by Chardan Capital Markets with a new price target

    Chardan Capital Markets downgraded Passage BIO from Buy to Neutral and set a new price target of $7.00

    4/21/26 7:30:00 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Passage BIO downgraded by Wedbush with a new price target

    Wedbush downgraded Passage BIO from Outperform to Neutral and set a new price target of $8.00

    4/21/26 7:29:39 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Posner Brian S bought $38,700 worth of shares (2,000 units at $19.35), increasing direct ownership by 17% to 13,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/13/26 4:46:19 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $45,360 worth of shares (8,000 units at $5.67), increasing direct ownership by 15% to 62,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    3/12/26 4:31:34 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Posner Brian S bought $45,180 worth of shares (3,000 units at $15.06), increasing direct ownership by 35% to 11,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/10/26 5:33:53 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    SEC Filings

    View All

    Amendment: SEC Form S-1/A filed by HCW Biologics Inc.

    S-1/A - HCW Biologics Inc. (0001828673) (Filer)

    4/24/26 5:30:12 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Dyne Therapeutics Inc.

    144 - Dyne Therapeutics, Inc. (0001818794) (Subject)

    4/24/26 4:47:05 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Dyne Therapeutics Inc.

    144 - Dyne Therapeutics, Inc. (0001818794) (Subject)

    4/24/26 4:46:22 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Financials

    Live finance-specific insights

    View All

    Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

    CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, April 28, 2026, to review the company's first quarter 2026 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call a

    4/22/26 8:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nerdy to Announce First Quarter 2026 Results on May 7, 2026

    Nerdy Inc. (NYSE:NRDY), a leading platform for delivering live online learning, today announced the Company will release its first quarter financial results for the period ended March 31, 2026 after the U.S. stock market closes on Thursday, May 7, 2026. Following the release, Nerdy management will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial and operating results. Interested parties in the U.S. may listen to the call by dialing 1-833-461-5787. International callers can dial 1-585-542-9983. The Access Code is 397446705. A live webcast of the call will also be available on Nerdy's investor relations website at https://www.nerdy.com/investor

    4/20/26 4:28:00 PM ET
    $NRDY
    Other Consumer Services
    Real Estate

    BlackSky to Host First Quarter 2026 Results Conference Call

    BlackSky Technology Inc. (NYSE: BKSY) will host a live webcast and conference call to discuss first quarter 2026 financial results and its business outlook on Thursday, May 7, 2026, at 8:30 a.m. EDT. A press release with BlackSky's financial results will be released in advance of the conference call that same day. To access the live webcast, please click here or visit the company's investor relations website at http://ir.blacksky.com and then select "News & Events". To eliminate wait times, conference call participants may pre-register here. After registering, a confirmation email will be sent with access details. The webcast and conference call will be archived on the investor relations

    4/16/26 4:30:00 PM ET
    $BKSY
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Leadership Updates

    Live Leadership Updates

    View All

    Humacyte Appoints Jim Mercadante as Chief Commercial Officer

    – Industry veteran with more than 25 years of experience will lead next phase of biotech company's commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific success in vascular and cardiothoracic surgery markets – – Appointment strengthens commercial leadership as Symvess® (acellular tissue engineered vessel-tyod) market launch accelerates and pipeline advances toward planned BLA filing in dialysis – DURHAM, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the appointment of Jim Merc

    4/22/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nerdy Inc. Appoints Atul Bagga as Chief Financial Officer

    Nerdy Inc. (NYSE:NRDY), a leading platform for delivering live online learning, today announced the appointment of Atul Bagga as Chief Financial Officer, effective April 6, 2026. "Atul is a disciplined and strategic financial leader with deep experience scaling high-growth technology organizations and driving operational excellence," said Chuck Cohn, Founder, Chairman and Chief Executive Officer of Nerdy. "As we enter our next phase of growth from a position of strength, we remain focused on disciplined execution, continued margin expansion, and durable value creation. Atul's background will be instrumental in building on the strong foundation we have established." In this role, Mr. Bag

    4/6/26 9:00:00 AM ET
    $JLL
    $NRDY
    $ZNGA
    Real Estate
    Finance
    Other Consumer Services
    EDP Services

    Humacyte Appoints Rick McElheny as Senior Vice President of Business Development

    - Mr. McElheney brings more than 15 of years' experience in corporate development and alliance management at biopharma companies. -  - He will work with the Company's leadership team to expand corporate collaborations to accelerate the development and commercialization of Humacyte's broad pipeline - DURHAM, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has appointed Rick McElheny to the role of Senior Vice President of Business Development. Mr. McElheny will work with the Company's leadership team to expan

    3/26/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGIL
    $AGMH
    $ALVR
    $ANNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fangdd Network Group Ltd.

    SC 13G - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:26:40 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Fangdd Network Group Ltd.

    SC 13G/A - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:24:27 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13D/A filed by Nerdy Inc.

    SC 13D/A - Nerdy Inc. (0001819404) (Subject)

    12/4/24 4:01:10 PM ET
    $NRDY
    Other Consumer Services
    Real Estate